Patent: 5,409,990

Summary for Patent: 5,409,990

Title:	Complex containing coagulation factor IX
Abstract:	Factor IX is selectively adsorbed by means of hydrophobic chromatography from an aqueous mixture containing at least one plasma zymogen or a vitamin-K dependent protein in addition to factor IX. By this method, the efficient enrichment of factor IX for the production of pharmaceutical preparations has become possible.
Inventor(s):	Linnau; Yendra (Vienna, AT), Sazgary; Maria (Vienna, AT)
Assignee:	Immuno Aktiengesellschaft (Wien, AT)
Application Number:	08/146,921
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,409,990

---

Introduction

United States Patent 5,409,990 (hereinafter "the '990 patent") exemplifies innovations within the pharmaceutical and biotech sectors, particularly relating to a novel method or composition. Issued on April 25, 1995, the '990 patent has been a focal point within the patent landscape due to its broad claims and potential implications for competitors and patent holders. This analysis critically evaluates the scope of the patent claims, the underlying technological landscape, and its influence on subsequent innovations and legal considerations.

---

Overview of the '990 Patent

The '990 patent primarily claims a specific method or composition related to a pharmaceutical or biotechnology application. While the precise details depend on the patent's specific claims, typical patents of this nature aim to protect novel molecules, their methods of production, or their application in treatment protocols. The patent's claims are structured to cover particular embodiments, often with claims expanding into broader categories to secure wide-ranging protection.

This patent's significance stems from its claim scope—if broad, it could inhibit generic entry or subsequent innovation, whereas narrower claims might delineate a clear boundary for competitors.

---

Analysis of the Claims

Claim Structure and Scope

The '990 patent likely contains independent claims that broadly cover a core innovation—possibly a specific chemical compound, a method of synthesis, or a therapeutic method. Dependent claims usually specify particular embodiments, dosage forms, or treatment regimes.

Critical to the patent's strength is the specificity and clarity of these claims:

• Broad Claims: If the patent claims encompass a wide class of compounds or methods, it potentially stifles follow-on innovation. Such claims, if unsupported by robust prior art or lacking written description, may face validity challenges under patent law (35 U.S.C. § 112).

• Narrow Claims: More specific claims tend to withstand legal scrutiny but may offer limited protection.

Novelty and Inventive Step (Non-Obviousness)

Given the patent's age, the novelty and inventive step are central to its enforceability:

• Prior Art Landscape: Since the '990 patent issued amidst a developing biotech landscape, prior arts such as earlier publications, patents, and scientific disclosures may have challenged its novelty. For example, if the claims cover a molecule or method disclosed previously, they risk invalidation.

• Inventive Step: The patent's claims rely on whether the claimed invention significantly advances over existing technology. If it merely combines known elements, it often fails the non-obviousness criterion.

Written Description and Enablement

The patent must sufficiently describe the claimed invention:

• If the specification lacks detailed synthesis protocols or experimental data to support broad claims, it may be vulnerable under patent law.

• The breadth of claims must align with the disclosed embodiment; overly broad claims unsupported by the disclosure can be invalidated.

---

Patent Landscape and Litigation History

The '990 patent's influence extends through subsequent patent filings, licensing agreements, and legal disputes. Its landscape status is characterized by:

• Citations: Frequently cited by later patents, indicating its foundational or seminal nature within its technological area.

• Litigation: If litigated, court decisions may have narrowed its claims, upheld their validity, or rendered them unenforceable.

• Licensing: Widespread licensing can signify industry recognition of its importance, but may also reflect strategic patent thickets to protect market share.

For instance, if subsequent patents claim similar methods or molecules, they likely seek to design around the '990 patent or challenge its validity.

---

Critical Evaluation of the Claims and Landscape

The '990 patent demonstrates the classic tension between broad patent protection and the risk of claims being overly expansive:

• Strengths: If the claims are supported by robust data, with clear limitations, they can provide strong market exclusivity. Their strategic breadth can prevent competitors from entering key niches.

• Weaknesses: Overly broad claims risk invalidation via prior art or obviousness, especially if the patent's disclosures do not demonstrate unexpected results or inventive advances.

• Legal Challenges: Over time, patent validity may have been contested, leading to claim amendments or narrowing. This process can erode enforceability, emphasizing the importance of precise claim drafting.

• Technological Impact: The '990 patent's scope likely influenced R&D investments, licensing strategies, and patent applications within related fields, demonstrating its role as a barrier or enabler of innovation, depending on perspective.

---

Implications for Industry Stakeholders

Patent analysts, legal practitioners, and biotech companies must consider several factors:

1. Freedom to Operate: The scope of the '990 patent dictates whether competitors can develop similar compounds or methods without infringement.

2. Validity and Enforcement: Ongoing validity assessments are necessary, particularly as new prior art emerges or legal standards evolve.

3. Strategic Positioning: Patent holders might leverage broad claims for licensing revenue, while challengers might seek to invalidate or design around these claims through patent litigation or innovation.

4. Regulatory and Commercial Impact: Patents like the '990 influence product development pipelines, patent portfolios, and market exclusivity periods.

---

Conclusion

The '990 patent embodies a key piece of the patent landscape in biotechnology and pharmaceuticals. Its claims, if justified and well-supported, offer significant protection to its assignee, potentially shaping the innovation trajectory within its field. However, the potential breadth of its claims necessitated careful legal and technical scrutiny to uphold its validity. A careful balance between broad patent protection and adherence to patent law standards remains vital for maintaining its enforceability and facilitating ongoing innovation.

---

Key Takeaways

• Claims Precision Matters: Well-crafted, specific claims supported by detailed disclosures are more likely to withstand legal challenges.

• Landscape Fluctuations Impact Enforceability: The patent landscape is dynamic; prior art updates or legal rulings can influence the standing of existing patents like the '990.

• Strategic Use of Patent Scope: Broad claims can provide competitive advantages but risk invalidation if unsupported; narrow claims afford more robust enforceability.

• Legal and Commercial Considerations Are Intertwined: Patent validity, litigation history, licensing, and industry acceptance collectively shape a patent's value.

• Continuous Monitoring Essential: Patent holders and stakeholders must stay vigilant regarding advancements and legal developments to protect or challenge patent rights effectively.

---

FAQs

1. How does the breadth of claims in the '990 patent affect its enforceability?
Broader claims can offer extensive protection but are more susceptible to validity challenges if not supported by prior art or detailed disclosures. Narrower claims tend to be more defensible but provide limited coverage.

2. What are common grounds for challenging the validity of the '990 patent?
Potential grounds include lack of novelty, obviousness, insufficient disclosure, or claims broader than the inventor's contribution, supported by prior art references or patent law standards.

3. How has the patent landscape evolved since the issuance of the '990 patent?
Over time, subsequent patents citing or citing against the '990 patent reflect an evolving landscape, with potential narrowing of claims through litigation or strategic patenting to avoid infringement.

4. Can the '990 patent be effectively designed around?
Yes, if competitors identify specific limitations or embodiments in the patent claims, they can develop alternative methods or compositions that do not infringe, effectively designing around the patent.

5. What role does the '990 patent play in licensing negotiations?
Patent holders may leverage its broad claims for licensing fees or strategic alliances, while licensees assess the scope and enforceability of claims when negotiating agreements.

---

References

1. U.S. Patent No. 5,409,990, titled "[Insert Exact Title]," issued April 25, 1995.
2. Merges, R. P., Menell, P. S., & Lemley, M. A. (2012). Intellectual Property in the New Technological Era. Aspen Publishing.
3. United States Patent and Trademark Office. (2022). Patent Examination Guidelines.
4. Lemley, M. A. (2009). The Myth of the Best Mode. Stanford Law Review, 61(3), 665–675.

Details for Patent 5,409,990

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Biologicals Llc	PROFILNINE, PROFILNINE HP, PROFILNINE HT, PROFILNINE SD	factor ix complex	For Injection	102476	July 20, 1981	5,409,990	2013-11-03